{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:45:41Z","timestamp":1787240741145,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Idiopathic intracranial hypertension (IIH) is a debilitating condition characterized by increased intracranial pressure often presenting with chronic migraine-like headache. Calcitonin gene-related peptide (CGRP) plays an important pathophysiological role in primary headaches such as migraine, whilst its role in IIH has not yet been established.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This longitudinal exploratory study included patients with IIH, episodic migraine (EM) in a headache-free interval and healthy controls (HC). Blood samples were collected from a cubital vein and plasma CGRP (pCGRP) levels were measured by standardized ELISA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 26 patients with IIH (mean age 33.2 years [SD 9.2], 88.5% female, median BMI 34.8\u00a0kg\/m<jats:sup>2<\/jats:sup> [IQR 30.0\u201341.4]), 30 patients with EM (mean age 27.6 years [7.5], 66.7% female) and 57 HC (mean age 25.3 years [5.2], 56.1% female) were included. pCGRP levels displayed a wide variation in IIH as well as in EM and HC on a group-level. Within IIH, those with migraine-like headache had significantly higher pCGRP levels than those with non-migraine-like headache (F<jats:sub>(2,524)<\/jats:sub>\u2009=\u200984.79; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and headache absence (F<jats:sub>(2,524)<\/jats:sub>\u2009=\u200984.79; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) throughout the observation period, explaining 14.7% of the variance in pCGRP levels. CGRP measurements showed strong intraindividual agreement in IIH (ICC 0.993, 95% CI 0.987\u20130.996, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). No association was found between pCGRP levels and ophthalmological parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although interindividual heterogeneity of pCGRP levels is generally high, migraine-like headache seems to be associated with higher pCGRP levels. CGRP may play a role in the headache pathophysiology at least in a subgroup of IIH.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01799-y","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T10:50:19Z","timestamp":1717498219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Plasma calcitonin gene-related peptide levels in idiopathic intracranial hypertension: an exploratory study"],"prefix":"10.1186","volume":"25","author":[{"given":"Nik","family":"Krajnc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Macher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Michl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Zaic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"W\u00f6ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Pemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Broessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bsteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"issue":"4","key":"1799_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s42399-021-00814-6","volume":"3","author":"MG Peng","year":"2021","unstructured":"Peng MG, Gokoffski KK (2021) Updates on recent developments in idiopathic intracranial hypertension. SN Compr Clin Med 3(4):1031\u20131041","journal-title":"SN Compr Clin Med"},{"issue":"5871","key":"1799_CR2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/298240a0","volume":"298","author":"SG Amara","year":"1982","unstructured":"Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298(5871):240\u2013244","journal-title":"Nature"},{"issue":"3","key":"1799_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/0014-2999(86)90238-4","volume":"124","author":"SD Brain","year":"1986","unstructured":"Brain SD, MacIntyre I, Williams TJ (1986) A second form of human calcitonin gene-related peptide which is a potent vasodilator. Eur J Pharmacol 124(3):349\u2013352","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1799_CR4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94(4):1099\u20131142","journal-title":"Physiol Rev"},{"issue":"4","key":"1799_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","volume":"158","author":"S Iyengar","year":"2017","unstructured":"Iyengar S, Ossipov MH, Johnson KW (2017) The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain 158(4):543\u2013559","journal-title":"Pain"},{"key":"1799_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/bs.pbr.2020.05.012","volume":"255","author":"ST Chen","year":"2020","unstructured":"Chen ST, Wu JW (2020) A new era for migraine: the role of calcitonin gene-related peptide in the trigeminovascular system. Prog Brain Res 255:123\u2013142","journal-title":"Prog Brain Res"},{"issue":"1","key":"1799_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s10194-018-0848-0","volume":"19","author":"K Messlinger","year":"2018","unstructured":"Messlinger K (2018) The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system. J Headache Pain 19(1):22","journal-title":"J Headache Pain"},{"issue":"1","key":"1799_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-017-0741-2","volume":"18","author":"WS Schou","year":"2017","unstructured":"Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M (2017) Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain 18(1):34","journal-title":"J Headache Pain"},{"issue":"2","key":"1799_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28(2):183\u2013187","journal-title":"Ann Neurol"},{"issue":"1","key":"1799_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/head.14026","volume":"61","author":"A Yiangou","year":"2021","unstructured":"Yiangou A, Mitchell JL, Fisher C, Edwards J, Vijay V, Alimajstorovic Z et al (2021) Erenumab for headaches in idiopathic intracranial hypertension: a prospective open-label evaluation. Headache 61(1):157\u2013169","journal-title":"Headache"},{"issue":"1","key":"1799_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee o","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International classification of Headache disorders, 3rd edition. Cephalalgia 38(1):1\u2013211","journal-title":"Cephalalgia"},{"key":"1799_CR12","doi-asserted-by":"crossref","unstructured":"Pruckner P, Mitsch C, Macher S, Krajnc N, Marik W, Novak K et al (2022) The Vienna Idiopathic Intracranial Hypertension (VIIH) database \u2013 an Austrian registry","DOI":"10.21203\/rs.3.rs-1638134\/v1"},{"issue":"8","key":"1799_CR13","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1167\/iovs.02-1100","volume":"44","author":"DA Rosser","year":"2003","unstructured":"Rosser DA, Cousens SN, Murdoch IE, Fitzke FW, Laidlaw DA (2003) How sensitive to clinical change are ETDRS logMAR visual acuity measurements? Invest Ophthalmol Vis Sci 44(8):3278\u20133281","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1799_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jnnp.45.1.13","volume":"45","author":"L Frisen","year":"1982","unstructured":"Frisen L (1982) Swelling of the optic nerve head: a staging scheme. J Neurol Neurosurg Psychiatry 45(1):13\u201318","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1799_CR15","doi-asserted-by":"publisher","first-page":"e34823","DOI":"10.1371\/journal.pone.0034823","volume":"7","author":"P Tewarie","year":"2012","unstructured":"Tewarie P, Balk L, Costello F, Green A, Martin R, Schippling S et al (2012) The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS ONE 7(4):e34823","journal-title":"PLoS ONE"},{"issue":"2","key":"1799_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1212\/WNL.0000000000012125","volume":"97","author":"A Aytulun","year":"2021","unstructured":"Aytulun A, Cruz-Herranz A, Aktas O, Balcer LJ, Balk L, Barboni P et al (2021) APOSTEL 2.0 recommendations for reporting quantitative Optical Coherence Tomography studies. Neurology 97(2):68\u201379","journal-title":"Neurology"},{"issue":"7","key":"1799_CR17","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00417-013-2337-0","volume":"251","author":"B Pemp","year":"2013","unstructured":"Pemp B, Kardon RH, Kircher K, Pernicka E, Schmidt-Erfurth U, Reitner A (2013) Effectiveness of averaging strategies to reduce variance in retinal nerve fibre layer thickness measurements using spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 251(7):1841\u20131848","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5 Suppl","key":"1799_CR18","first-page":"807","volume":"98","author":"Classification of diabetic retinopathy from fluorescein angiograms","year":"1991","unstructured":"Classification of diabetic retinopathy from fluorescein angiograms (1991) ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98(5 Suppl):807\u2013822","journal-title":"Ophthalmology"},{"key":"1799_CR19","first-page":"203","volume":"14","author":"KC Ossoinig","year":"1975","unstructured":"Ossoinig KC (1975) A-scan echography and orbital disease. Mod Probl Ophthalmol 14:203\u2013235","journal-title":"Mod Probl Ophthalmol"},{"issue":"Pt 4","key":"1799_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/eye.1988.66","volume":"2","author":"HR Atta","year":"1988","unstructured":"Atta HR (1988) Imaging of the optic nerve with standardised echography. Eye (Lond) 2(Pt 4):358\u2013366","journal-title":"Eye (Lond)"},{"issue":"13","key":"1799_CR21","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1177\/03331024211024161","volume":"41","author":"K Messlinger","year":"2021","unstructured":"Messlinger K, Vogler B, Kuhn A, Sertel-Nakajima J, Frank F, Broessner G (2021) CGRP measurements in human plasma - a methodological study. Cephalalgia 41(13):1359\u20131373","journal-title":"Cephalalgia"},{"key":"1799_CR22","unstructured":"in The Prevention and Treatment of Missing Data in clinical trials. (2010) : Washington (DC)"},{"issue":"8","key":"1799_CR23","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/head.12179","volume":"53","author":"ME Bigal","year":"2013","unstructured":"Bigal ME, Walter S, Rapoport AM (2013) Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 53(8):1230\u20131244","journal-title":"Headache"},{"issue":"6","key":"1799_CR24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14(6):338\u2013350","journal-title":"Nat Rev Neurol"},{"key":"1799_CR25","doi-asserted-by":"crossref","unstructured":"Buse DC, Greisman JD, Baigi K, Lipton RB (2019) Migraine Progression: A Systematic Review. Headache ; 59 (3): 306\u2013338","DOI":"10.1111\/head.13459"},{"issue":"5","key":"1799_CR26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1600-0404.2007.00905.x","volume":"116","author":"N Celebisoy","year":"2007","unstructured":"Celebisoy N, Gokcay F, Sirin H, Akyurekli O (2007) Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 116(5):322\u2013327","journal-title":"Acta Neurol Scand"},{"issue":"9","key":"1799_CR27","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.1007\/s10072-022-06200-x","volume":"43","author":"R De Simone","year":"2022","unstructured":"De Simone R, Sansone M, Russo C, Miele A, Stornaiuolo A, Braca S (2022) The putative role of trigemino-vascular system in brain perfusion homeostasis and the significance of the migraine attack. Neurol Sci 43(9):5665\u20135672","journal-title":"Neurol Sci"},{"issue":"3","key":"1799_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/WCO.0000000000000440","volume":"30","author":"C Ramon","year":"2017","unstructured":"Ramon C, Cernuda-Morollon E, Pascual J (2017) Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine. Curr Opin Neurol 30(3):281\u2013286","journal-title":"Curr Opin Neurol"},{"issue":"14","key":"1799_CR29","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","volume":"81","author":"E Cernuda-Morollon","year":"2013","unstructured":"Cernuda-Morollon E, Larrosa D, Ramon C, Vega J, Martinez-Camblor P, Pascual J (2013) Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 81(14):1191\u20131196","journal-title":"Neurology"},{"issue":"1","key":"1799_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s10194-020-01182-7","volume":"21","author":"A Yiangou","year":"2020","unstructured":"Yiangou A, Mitchell JL, Vijay V, Grech O, Bilton E, Lavery GG et al (2020) Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. J Headache Pain 21(1):116","journal-title":"J Headache Pain"},{"issue":"4","key":"1799_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10072-010-0229-1","volume":"31","author":"R De Simone","year":"2010","unstructured":"De Simone R, Ranieri A, Fiorillo C, Bilo L, Bonavita V (2010) Is idiopathic intracranial hypertension without papilledema a risk factor for migraine progression? Neurol Sci 31(4):411\u2013415","journal-title":"Neurol Sci"},{"key":"1799_CR32","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3389\/fneur.2018.01090","volume":"9","author":"F Bono","year":"2018","unstructured":"Bono F, Curcio M, Rapisarda L, Vescio B, Bombardieri C, Mangialavori D et al (2018) Cerebrospinal fluid pressure-related features in chronic headache: a prospective study and potential diagnostic implications. Front Neurol 9:1090","journal-title":"Front Neurol"},{"key":"1799_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.npep.2017.04.008","volume":"65","author":"S Sampaolo","year":"2017","unstructured":"Sampaolo S, Liguori G, Vittoria A, Napolitano F, Lombardi L, Figols J et al (2017) First study on the peptidergic innervation of the brain superior sagittal sinus in humans. Neuropeptides 65:45\u201355","journal-title":"Neuropeptides"},{"issue":"2","key":"1799_CR34","first-page":"327","volume":"161","author":"PJ Goadsby","year":"2009","unstructured":"Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR (2009) Neurobiol Migraine Neurosci 161(2):327\u2013341","journal-title":"Neurobiol Migraine Neurosci"},{"key":"1799_CR35","doi-asserted-by":"publisher","first-page":"925748","DOI":"10.3389\/fneur.2022.925748","volume":"13","author":"F Frank","year":"2022","unstructured":"Frank F, Kaltseis K, Messlinger K, Broessner G (2022) Short report of longitudinal CGRP-Measurements in migraineurs during a hypoxic challenge. Front Neurol 13:925748","journal-title":"Front Neurol"},{"issue":"1","key":"1799_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/acn3.50972","volume":"7","author":"A Manouchehrinia","year":"2020","unstructured":"Manouchehrinia A, Piehl F, Hillert J, Kuhle J, Alfredsson L, Olsson T et al (2020) Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol 7(1):139\u2013143","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"1799_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-018-0883-x","volume":"19","author":"MJ Lee","year":"2018","unstructured":"Lee MJ, Lee SY, Cho S, Kang ES, Chung CS (2018) Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. J Headache Pain 19(1):53","journal-title":"J Headache Pain"},{"issue":"1","key":"1799_CR38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/WNO.0000000000000777","volume":"39","author":"DI Friedman","year":"2019","unstructured":"Friedman DI (2019) Headaches in idiopathic intracranial hypertension. J Neuroophthalmol 39(1):82\u201393","journal-title":"J Neuroophthalmol"},{"key":"1799_CR39","doi-asserted-by":"crossref","unstructured":"Bsteh G, Macher S, Krajnc N, Pruckner P, Marik W, Mitsch C et al (2023) Idiopathic intracranial hypertension presenting with migraine phenotype is associated with unfavorable headache outcome. J Headache Pain","DOI":"10.21203\/rs.3.rs-2017861\/v1"},{"key":"1799_CR40","doi-asserted-by":"publisher","first-page":"108136","DOI":"10.1016\/j.clineuro.2024.108136","volume":"237","author":"AK Ak","year":"2024","unstructured":"Ak AK, Gemici YI, Batum M, Karakas B, Ozmen EY, Gokcay F et al (2024) Calcitonin gene-related peptide (CGRP) levels in peripheral blood in patients with idiopathic intracranial hypertension and migraine. Clin Neurol Neurosurg 237:108136","journal-title":"Clin Neurol Neurosurg"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01799-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01799-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01799-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T10:50:26Z","timestamp":1717498226000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01799-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1799"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01799-y","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"24 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the Medical University Vienna (ethical approval number: 2216\/2020). Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Nik Krajnc: has participated in meetings sponsored by, received speaker honoraria or travel funding from Alexion, BMS\/Celgene, Janssen-Cilag, Merck, Novartis, Roche and Sanofi-Genzyme and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Florian Frank: nothing to disclose.Stefan Macher: declares no conflict of interest relevant to this study.Martin Michl: declares no conflict of interest relevant to this study.Nina M\u00fcller: declares no conflict of interest relevant to this study.Sarah Maier: declares no conflict of interest relevant to this study.Sina Zaic: declares no conflict of interest relevant to this study.Berthold Pemp: has received honoraria for speaking from Novartis.Christian W\u00f6ber: has received honoraria consultancy\/speaking from Apomedica, Curelator, Eli Lilly, Gr\u00fcnenthal, Hermes, Lundbeck, Novartis, Pfizer, Ratiopharm\/Teva, and Stada.Gregor Broessner: has received unrestricted grants, honoraria, personal fees, travel grants from Allergan, AMGEN, Menarini, Pfizer, Linde AG, Astra Zeneca, St. Jude Medical, Reckitt Benkiser, Novartis, TEVA, Fresenius, Janssen Cilag, Lilly, \u00d6sterreichische Gesellschaft f\u00fcr Neurologie (\u00d6GN), European Headache Foundation (EHF), \u00d6sterreichische Kopfschmerzgesellschaft (\u00d6KSG), \u00d6sterreichische Akademie der Wissenschaften (\u00d6AW) and European FP7 Framework Programme.Gabriel Bsteh: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene\/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene\/BMS, Novartis, Roche, Sanofi-Genzyme and Teva. He has received unrestricted research grants from Celgene\/BMS and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}